"HOST THERAPY" STRATEGY FOR TUBERCULOSIS AND ELIMINATION OF THE IMPORTANCE OF INTERFERON - GAMMA IN THE PATHOGENESIS AND THERAPY OF TUBERCULOSIS INFECTION

Sultonov G’.I.

Authors

Sultonov G’.I. Andijan State Medical Institute Assistant, Department of Phthisiology and Pulmonology

Keywords:

Host-directed therapy, tuberculosis, mycobacterium tuberculosis, immunomodulation, interferon-gamma, pathogenesis of tuberculosis, immunotherapy, host immune response.

Abstract

The possibilities of immunotropic drugs should be used in conditions of constantly changing properties of the pathogen (genotype, virulence, resistance to anti-tuberculosis drugs) with a prolonged, complication-prone and relapsing course of the disease with the formation of secondary immunological insufficiency requiring correction. As an adjunct to chemotherapy, HDT can be administered at the beginning of a standard treatment regimen to correct a general immunological imbalance or towards the end of treatment to enhance "host immunity" to prevent potential recurrence.

References

Balasanyants G.S., Ruzanov D.Yu. `Immunotherapeutic role of interferon-γ at tuberculosis. Immunologiya, 2022, vol. 43, no. 3, pp. 343-351. (In Russ.)

Voronkova O.V., Urazova O.I., Novitskiy V.V., Strelis A.K. Immunopatologiya tuberkuleza legkikh. [Immune pathology of pulmonary tuberculosis]. Tomsk, Tomsk University Publ., 2007.

Esimova I.E. Molekulyarnyye mekhanizmy disregulyatsii retseptor- i tsitokin-oposredovannoy aktivatsii T-limfotsitov pri tuberkuleze legkikh. Avtoref. diss. dokt. med. nauk. [Molecular mechanisms of dysregulation of receptor- and cytokine-mediated activation of T-lymphocytes in pulmonary tuberculosis. Synopsis of Doct. Diss.]. Tomsk, 2018. Available: https://search. rsl.ru/ru/record/01008715107 Accessed December 1, 2023.

Zakharova M.V., Stakhanov V.A., Mezentseva M.V. Features of the cytokine profile and interferon status of patients with infiltrative pulmonary tuberculosis. Infectious Diseases (Infektsionnye Bolezni), 2011, vol. 9, no. 1,

pp. 47-50. (In Russ.)

Ivanov A.K., Sologub T.V., Panteleev A.M., Sukhanov D.S., Romantsov M.G., Kovalenko A.L. Comprehensive treatment of HIV-positive tuberculosis patients with cycloferon. Eksper. I Klin Farmakol., 2010, no. 7, pp. 32-35. (In Russ.)

Ketlinskiy S.A., Simbirtsev A.S. Tsitokiny. [Cytokines]. St. Peterburg, Foliant Publ, 2008.

Kiselev O.I., Ershov F.I., Deeva E.G. Interferon-gamma: novy tsitokin v klinicheskoy praktike. Ingaron. [Interferon-gamma: a new cytokine in the clinical practice. Ingaron]. Moscow, Dimitreyd Graphic Group Publ., 2007.

Knoring B.E., Davydova N.I., Basek T.F., Nitsa N.A., Elkin A.V. Immune indexes in patients with progressive fibrous-cavernous tuberculosis dependent on severity of destructive changes in the lungs. Medical Immunology (Russia), 2012, vol. 14, no. 4-5, pp. 329-336. (In Russ.)

Linge I.A., Apt A.S. A controversial role of neutrophils in tuberculosis infection pathogenesis. Infektsiya I Immunitet, 2021, vol. 11, no. 5, pp. 809-819. (In Russ.) https://doi.org/10.15789/2220-7619-ACR-1670

Lutsky A.A., Zhirkov A.A., Lobzin D.Yu., Rao M., Alekseeva L.A., Meyrer M., Lobzin Yu.V. Interferon-γ: biological function and application for study of cellular immune response. Journal Infektologii, 2015, vol. 7, no. 4, pp. 10-22. (In Russ.)

Maslennikov A.A., Obolonkova N.I. The effectiveness of Ingaron in comprehensive therapy of patients with destructive pulmonary tuberculosis with bacterial excretion. Nauchnyy Rezultat. Ser. Meditsina I Farmatsiya, 2016, vol. 2, no. 7, pp. 10-16. (In Russ.)

Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Russkikh A.E. Medications for short-course chemotherapy of drug resistant tuberculosis and their effect on the host. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 8, pp. 54-64. (In Russ.) http://doi.org/10.21292/2075-1230-2022-100-8-54-64